$180 million UroCor deal advances Dianon's strategy
This article was originally published in Clinica
Dianon Systems, a US cancer diagnostic pathology company, has signed a definitive agreement to acquire UroCor, a urological diagnosis company, in a share transaction that values UroCor at $180 million. The deal creates a company with a leading share in the urology sector of the cancer diagnostics market in the US. Dianon had tried and failed to acquire the company three years ago.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.